Humacyte (HUMA) Common Equity (2020 - 2026)

Humacyte (HUMA) has reported Common Equity for 7 consecutive years, with $31.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 91.07% year-over-year to $31.3 million in Q2 2026; TTM through Jun 2026 was $31.3 million, a 91.07% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 105.9% from the prior year.
• Common Equity was $31.3 million for Q2 2026 at Humacyte, up from $11.6 million in the prior quarter.
• Over five years, Common Equity peaked at $350.0 million in Q2 2025 and troughed at -$63.7 million in Q3 2024.
• A 5-year average of $54.7 million and a median of $33.7 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 488.82% in 2024 and jumped 1337.32% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $116.9 million in 2022, then sank by 88.42% to $13.5 million in 2023, then tumbled by 488.82% to -$52.7 million in 2024, then surged by 105.9% to $3.1 million in 2025, then jumped by 905.5% to $31.3 million in 2026.
• The last three Common Equity figures came in at $31.3 million (Q2 2026), $11.6 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.